Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Differential trends in survival after allogeneic transplantation for MDS and MDS/MPN in a real-world experience

View Full Paper
Ask AI
Bookmark
Share

Authors

HIHidehiro ItonagaSKShuhei KurosawaAMAtsushi Marumo

Discussion

Loading...

Member takes

Overview

Observational analysis shows improved survival in myeloid neoplasms post-allo-HSCT, indicating treatment advancements are effective.

Key Points

  • Survival rates in myeloid neoplasms improved after allogeneic transplantation, with specific gains noted for chronic myelomonocytic leukemia.
  • Overall survival for advanced myelodysplastic/myeloproliferative neoplasms significantly enhanced, with notable increases across time periods.
  • Assessment using Cox proportional hazards models highlighted improved non-relapse mortality in early and middle grafting periods.
  • Continued research is crucial to address treatment gaps in specific myeloid neoplasm categories for better outcomes.

Cite This Study

Itonaga et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d856https://doi.org/10.1182/blood-2025-3843
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Trends in transplantation for patients with myelodysplastic syndrome across recent decades: A registry-based study on behalf of the chronic malignancies working of the EBMT2025
  2. 2National Trends and In-Hospital Outcomes of Hematopoietic Stem Cell Transplant in Myelodysplastic Syndromes, 2016–20202025
  3. 3Temporal trends in overall survival among patients with high-risk MDS: Insights from the spanish MDS registry (RESMD)2025
  4. 4Myelodysplastic/myeloproliferative overlap neoplasms: Clinicopathological features, treatment strategies, and outcomes — a UK multicentre cohort Study2025
  5. 5Older age and complex karyotype are the main predictors of mortality irrespective of allogeneic transplant in therapy-related myeloid neoplasms: A single‑center retrospective cohort2025